Alembic Pharmaceuticals has posted its consolidated results for the quarter ended June 30, 2014. The net sales is up by 16 per cent to Rs 496.1 crores against Rs 428.8 crores in the corresponding quarter last year. Profit before tax has been up by 40 per cent to Rs 84.9 crores against Rs 60.5 crores in the corresponding quarter last year. Net profit after tax up by 39 per cent to Rs 64.7 crores against Rs 46.6 crores in the corresponding quarter last year. EBITDA margins is 19.5 per cent at Rs 96.7 crores against 16.7 per cent at Rs 71.5 crores in the corresponding quarter last year. Domestic branded formulations sales up 16 per cent for the quarter at Rs 223.3 crores against Rs 192 crores in corresponding quarter last year. The international generic formulations sales is up 33 per cent for the quarter at Rs 113.8 crores against Rs 85.5 crores in corresponding quarter last year. Three ANDA application were filed for the quarter taking cumulative ANDA filings of the company to 64. Three ANDA approvals were received for the quarter taking cumulative ANDA/NDA approvals to 35 (including five tentative approvals).
The India branded formulations business posted sales of Rs 223.3 crores against Rs 192 crores with a 16 per cent growth over the corresponding quarter of the previous year. Speciality and acute segments grew by 25 per cent and four per cent respectively in current quarter. The international generic formulation posted growth of 33 per cent and posted sales of Rs 113.8 crores against Rs 85.5 crores over the corresponding quarter last year.
During the quarter three ANDA applications were filed taking cumulative ANDA filings of the company to 64. During the quarter three ANDA approvals were received taking cumulative ANDA/NDA approvals to 35 (including five tentative approvals).
EP News Bureau- Mumbai
- Advertisement -
